Boston Sci chief stepping down; Hib vax no longer scarce, CDC says;

> Boston Scientific CEO James Tobin will leave the device maker, to be succeeded by Raymond Elliott, ex-chief of the orthopedic device firm Zimmer Holdings. Report

> The government declared an end to a shortage of a childhood vaccine that protects against Haemophilus influenza type B, a shot that had grown scarce after a 2007 Merck recall. Report

> Singapore's industrial production unexpectedly increased in May as pharmaceutical companies boosted output. Report

> European regulators recommended that a 50-year-old painkiller be withdrawn from the market out of concern that patients have been fatally overdosing. Report

> Novavax appointed Stanley Erck, who served most recently as president and CEO of vaccine developer Iomai, to the company's Board of Directors. Report

> UCB and Sepracor filed suit in U.S. District Court against Synthon Pharmaceuticals, alleging patent infringement related to its generic version of Xyzal solution. Report

Biotech News

> Lexington, MA-based start-up Taris Biomedical has snared $15 million in its Series A, which will be put to use advancing a new drug-device therapy for bladder disease. Taris had been flying under the radar prior to its emergence at a conference yesterday. Report

> An experimental cancer therapy that's one of a new class of PARP inhibitors produced some surprisingly positive results in a small study of cancer victims who share BRCA1 and BRCA2 genetic mutations. Report

> FDA officials heard an earful yesterday from consumer advocates who want to put drugs and data in a public spotlight--a prospect that makes many developers distinctly uncomfortable. Report

> It turns out that Sanofi-Aventis' plans to restructure its R&D operations may have as much to do with cutting costs as it does with boosting outside development alliances. Report

> Insmed's lead drug failed to show efficacy in a mid-stage clinical trial of a genetic condition called myotonic muscular dystrophy and investors swiftly hammered the stock, sending down shares more than 50 percent on the news. Report

And Finally... Swine flu has infected as many as 1 million Americans, with 6 percent or more of some urban populations infected. Report

Suggested Articles

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.